Facebook
Twitter
LinkedIn
ForwardWebcast - ASCO Direct™ Highlights: 2022 Official Annual Meeting Review
This accredited continuing education activity “Webcast - ASCO Direct™ Highlights: 2022 Official Annual Meeting Review”, is recorded from the live meeting held on 6/18/2022 - 6/19/2022.
If you participated in the live meeting titled - ASCO Direct™ Highlights: 2022 Official Annual Meeting Review on 6/18/2022-6/19/2022 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that meeting on 6/18/2022-6/19/2022. However, you may enroll in this activity to review the contents.
The recorded lectures and subsequent discussions feature some of the most well-known experts in the field of hematology and oncology who provide a comprehensive overview of noteworthy data presented at the 2022 ASCO Annual Meeting (ASCO2022) in June of 2022. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field and a scientific abstract session. Expert faculty will place abstract findings from ASCO2022 into clinical context and discuss how the results may change the current standard of care.
REGISTRATION FEES:
Registration fee for this activity is $0 for everybody.
Target Audience
- Medical oncologists
- Radiation oncologists
- Surgical oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
- Oncology nurses
Learning Objectives
At the conclusion of the activity, participants will be able to:
- Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
- Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
- Explain how to effectively manage side-effects associated with cancer treatment
- Review abstracts presented at ASCO® 2022 and discuss their application in clinical settings
This educational activity features recorded videos from the live meeting titled - ASCO Direct™ Highlights: 2022 Official Annual Meeting Review held 6/18/2022-6/19/2022.
The videos are placed in the following order. Feel free to view the content that is relevant to you.
Participants should claim continuing education credits to the extent of their participation.
HEMATOLOGIC MALIGNANCIES SESSION
30 minutes: MDS/leukemias - Dr. Anna Halpern
30 minutes: Multiple myeloma - Dr. Shaji Kumar
30 minutes: Lymphoma & CLL - Dr. Ryan Lynch
THORACIC ONCOLOGY SESSION
30 minutes: Early-stage lung cancer - Dr. Christina Baik
30 minutes: Targeted therapies in lung cancer - Dr. Jack West
25 minutes: Immunotherapy in lung cancer - Dr. Rafael Santana-Davila
30 minutes: Covid-19: Implication for cancer care - Dr. Dimpy Shah
GENERAL ONCOLOGY SESSION
30 minutes: Sarcoma updates - Dr. Michael Wagner
30 minutes: Brain tumor updates - Dr. Vyshak Venur
30 minutes: Head neck cancer - Dr. Ezra Cohen
25 minutes: Gynecologic cancer - Dr. Kalyan Banda
GENITOURINARY CANCER SESSION
30 minutes: Prostate cancer - Dr. Evan Yu
30 minutes: Bladder cancer - Dr. Petros Grivas
35 minutes: Kidney cancer - Dr. Scott Tykodi
SKIN CANCER
30 minutes: Melanoma update - Dr. Shailender Bhatia
30 minutes: Non-melanoma skin cancers - Dr. Evan Hall
GI CANCER SESSION
40 minutes: Colorectal cancer - Dr. G. Weldon Gilcrease
30 minutes: Hepatobiliary malignancies - Dr. Daneng Li
30 minutes: Other GI cancers - Dr. David Zhen
BREAST CANCER SESSION
30 minutes: Early-stage breast cancer - Dr. Poorni Manohar
35 minutes: Metastatic breast cancer 1 (hormone receptor positive) - Dr. Hope Rugo
35 minutes: Metastatic breast cancer 2 (HER2 +ve and triple negative breast cancer) - Dr. Mark Pegram
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity. All conflict of interests have been identified and mitigated.
Glynn Weldon Gilcrease, MD has no relevant financial relationships to disclose at this time.
Kalyan Banda, MD has no relevant financial relationships to disclose at this time.
Petros Grivas, MD, PHD has a financial relationship (Independent contractor) with Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Seattle Genetics, Pfizer, Janssen, Mirati Therapeutics, Exelixis, Roche, Genentech, Dyania Health, Infinity Pharmaceuticals, QED Therapeutics, 4D Pharma PLC, Regeneron Pharmaceuticals, Astellas Pharma, Guardant Health, Urogen pharma, Gilead Sciences, Silverback Therapeutics; financial relationship (Grant or Contract) with Research funding to the institution: Pfizer, Clovis Oncology, Bavarian Nordic, Bristol-Myers Squibb, Debiopharm Group, Merck, QED Therapeutics, GlaxoSmithKline, Mirati Therapeutics, EMD Serono, G1 Therapeutics, Gilead Sciences.
Vyshak Venur, MD has a financial relationship (Independent contractor) with Seagen.
Scott Tykodi, MD, PhD has a financial relationship (Independent contractor) with Exelixis; financial relationship (Independent contractor) with Merck; financial relationship (Independent contractor) with Bristol Myers Squibb; financial relationship (Independent contractor) with Intellisphere, LLC; financial relationship (Grant Or Contract) with Bristol Myers Squibb; financial relationship (Grant Or Contract) with Genentech; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Grant Or Contract) with Nektar Therapeutics; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Exelixis; financial relationship (Grant Or Contract) with Jounce Therapeutics.
David Aboulafia, MD has no relevant financial relationships to disclose at this time.
Jessica Hawley, MD, MS has a financial relationship (Grant Or Contract) with Regeneron; financial relationship (Grant Or Contract) with Dendreon; financial relationship (Independent contractor) with Seagen.
Nikhil Kamat, MD has no relevant financial relationships to disclose at this time.
Kelly Paulson, MD, PhD has no relevant financial relationships to disclose at this time.
Joseph Rosales, MD has no relevant financial relationships to disclose at this time.
Tanya Wahl, MD has no relevant financial relationships to disclose at this time.
Fengting Yan, MD has no relevant financial relationships to disclose at this time.
Christina Baik, MD MPH has a financial relationship (Grant Or Contract) with Blueprint Medicines; financial relationship (Grant Or Contract) with Guardant; financial relationship (Grant Or Contract) with AstraZeneca; financial relationship (Grant Or Contract) with Turning Point; financial relationship (Grant Or Contract) with Takeda; financial relationship (Grant Or Contract) with Daiichi Sankyo.
Ezra Cohen, MD, FRCPSC, FASCO has a financial relationship (Independent contractor) with Hoopika; financial relationship (Independent contractor) with Kahr Medical; financial relationship (Independent contractor) with MSD; financial relationship (Independent contractor) with Ayala; financial relationship (Independent contractor) with Kinnate Biopharma; financial relationship (Independent contractor) with Eisai; financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with Mirati; financial relationship (Independent contractor) with Roche; financial relationship (Independent contractor) with Psioxus Therapeutics; financial relationship (Stock) with Primmune Therapeutics; financial relationship (Independent contractor) with Cel Sci; financial relationship (Independent contractor) with Istari; financial relationship (Independent contractor) with Merck; financial relationship (Independent contractor) with Pangea Therapeutics; financial relationship (Independent contractor) with NCCN; financial relationship (Independent contractor) with Axelia; financial relationship (Independent contractor) with ImmunoSensor; financial relationship (Independent contractor) with Mana Therapeutics; financial relationship (Independent contractor) with Nectin Tx; financial relationship (Independent contractor) with Kura; financial relationship (Stock) with Kinnate Biopharma.
Evan Hall, MD, MPhil has a financial relationship (Other) with Nektar; financial relationship (Other) with Bristol-Myers-Squibb; financial relationship (Other) with Replimune; financial relationship (Other) with NiKang; financial relationship (Other) with ImCheck.
Anna Halpern, MD has a financial relationship (Other) with Imago Biosciences; financial relationship (Professional Services) with Agios Pharmaceuticals; financial relationship (Other) with Jazz pharmaceuticals; financial relationship (Other) with Incytes Pharmaceuticals; financial relationship (Other) with Bayer; financial relationship (Other) with Karyopharm Therapeutics; financial relationship (Professional Services) with Notable Labs; financial relationship (Other) with Gilead Sciences; financial relationship (Professional Services) with Abbvie.
Shaji Kumar, MD has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ; financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen, Janssen, , Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio, Molecular Templates.
Daneng Li has a financial relationship (Independent contractor) with Eisai; financial relationship (Independent contractor) with Merck; financial relationship (Independent contractor) with TerSera Therapeutics; financial relationship (Independent contractor) with Adagene; financial relationship (Independent contractor) with Ipsen; financial relationship (Independent contractor) with Coherus; financial relationship (Grant Or Contract) with Brooklyn ImmunoTherapeutics; financial relationship (Independent contractor) with Genentech; financial relationship (Independent contractor) with Servier; financial relationship (Grant Or Contract) with AstraZeneca; financial relationship (Independent contractor) with Exelixis; financial relationship (Independent contractor) with QED.
Ryan Lynch has a financial relationship (Grant Or Contract) with Juno Therapeutics; financial relationship (Grant Or Contract) with Genentech; financial relationship (Grant Or Contract) with TG Therapeutics; financial relationship (Grant Or Contract) with Cyteir; financial relationship (Grant Or Contract) with Bayer; financial relationship (Grant Or Contract) with Incyte; financial relationship (Other) with Morphosys; financial relationship (Grant Or Contract) with RAPT; financial relationship (Grant Or Contract) with SeaGen.
Poorni Manohar, MD has no relevant financial relationships to disclose at this time.
Mark Pegram, MD has no relevant financial relationships to disclose at this time.
Hope Rugo has a financial relationship (Grant Or Contract) with Boehringer Ingelheim; financial relationship (Grant Or Contract) with Gilead; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Daiichi; financial relationship (Grant Or Contract) with Ayala; financial relationship (Professional Services) with NAPO; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Grant Or Contract) with Roche ; financial relationship (Grant Or Contract) with Sermonix; financial relationship (Grant Or Contract) with AstraZeneca; financial relationship (Professional Services) with Samsung; financial relationship (Grant Or Contract) with Lilly; financial relationship (Grant Or Contract) with Macrogenics; financial relationship (Grant Or Contract) with Polyphor; financial relationship (Professional Services) with Puma; financial relationship (Grant Or Contract) with Novartis; financial relationship (Grant Or Contract) with Seattle Genetics.
Rafael Santana-Davila, MD has no relevant financial relationships to disclose at this time.
Dimpy Shah, MD, PhD has no relevant financial relationships to disclose at this time.
Michael Wagner, M.D. has a financial relationship (Independent contractor) with Epizyme; financial relationship (Independent contractor) with Deciphera; financial relationship (Independent contractor) with Adaptimmune.
Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA has a financial relationship (Independent contractor) with Mirati; financial relationship (Independent contractor) with Merck; financial relationship (Independent contractor) with Takeda; financial relationship (Independent contractor) with Genentech/Roche; financial relationship (Independent contractor) with AstraZeneca; financial relationship (Independent contractor) with Regeneron.
Evan Yu, Professor of Medicine, University of Washington has a financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with Exelixis; financial relationship (Independent contractor) with Bayer; financial relationship (Independent contractor) with Advanced Accelerator Applications; financial relationship (Independent contractor) with Merck.
David Zhen, MD has a financial relationship (Grant Or Contract) with Daiichi-Sankyo; financial relationship (Grant Or Contract) with SeaGen; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Astra Zeneca.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
The live portion of this activity and all associated enduring materials are supported with independent medical education grants from the following companies:
- Jazz Pharmaceuticals
- Seagen, Inc.
- Exact Sciences
Important Information about Claiming CME for this activity:
If you participated in the live meeting titled - ASCO Direct™ Highlights: 2022 Official Annual Meeting Review on 6/18/2022-6/19/2022 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that live meeting on 6/18/2022-6/19/2022. However, you can still enroll in this activity and review the contents as needed.
The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.
The Binaytara Foundation designates this enduring activity for a maximum of 11 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.
ABSM Maintenance of Certificate Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Available Credit
- 11.00 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 11.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 11.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.